POZ January-February 2015
POZ January-February 2015
In every issue, you’ll find the hottest topics of interest to our readers along with cutting-edge health information.
Also Available On:
Features
Straight Talk
Advocating for HIV peer education programs in and out of prison
Burden of Proof
Is criminalizing HIV ever a good idea?
From the Editor
Philadelphia Freedom
According to the CDC, an estimated 1 in 7 persons living with HIV pass through a correctional facility each year.
Feedback
Letters-January/February 2015
In the article “PrEP and Prejudice” (October/November 2014), Benjamin Ryan wrote about Truvada’s use as pre-exposure prophylaxis (PrEP)...
POZ Q+A
Vertical Challenge
The Elizabeth Glaser Pediatric AIDS Foundation believes ending mother-to-child transmission is closer than ever.
POZ Planet
AIDS and Ebola
History repeats itself in this tale of two global epidemics.
Say What? Laverne Cox Edition
At the 2014 United States Conference on AIDS, Laverne Cox gave a speech that was simultaneously entertaining, informative and very intimate.
Gender Studies
Iris House clients see excellent viral suppression rates. Here’s why.
Evel Dick’s Most Unusual Diagnosis Story
There’s never a good time to learn you have HIV. But imagine getting the news while filming the reality show Big Brother. That’s what happened...
Voices
My Refuge
Actor and writer Bruce Ward shares how going (or sometimes just trying to go) to the gym helps him cope as a long-term survivor.
Care and Treatment
FDA OKs New Boosting Agent
The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences’ Tybost (cobicistat) as a boosting agent to raise the drug levels..
Vitekta Gets FDA Approval
The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences’ integrase strand transfer inhibitor Vitekta (elvitegravir) for HIV-p...
New Form of Viread Is Kinder to the Kidneys
Gilead Sciences has applied to the U.S. Food and Drug Administration (FDA) for approval of the first single-pill combination tablet to...
New HIV Antibody Target Could Have Many Benefits
National Institutes of Health (NIH) researchers have found a new site on HIV’s surface that is vulnerable to a powerful broadly neutralizing a...
Research Notes
Prevention: Americans Adhered Well to PrEP in iPrEx
A new analysis of the global iPrEx study, which proved Truvada’s (tenofovir/emtricitabine) efficacy as pre-exposure prophylaxis (PrEP), found...
Treatment: Hope for ARV-Free Treatment
New laboratory research has shown that what are known as broadly neutralizing antibodies (BNAs) can block HIV from entering or replicating ins...
Cure: What Cured the Berlin Patient?
A small primate study has suggested that the radiation element of the leukemia treatment that Timothy Ray Brown (a.k.a. the Berlin Patient) re...
Concerns: HIV Not on Young Gays’ Radar
A new nationally representative survey of American gay and bisexual men paints the image of a population largely unconcerned about HIV
POZ Survey Says
Online Chatter
According to Nielsen’s Social Media Report, Americans spend nearly 25 percent of their time on social networks and blogs.
POZ Heroes
Justice For All
Venton Jones actually got involved in AIDS work a year before he was diagnosed with HIV.
